These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6781893)

  • 1. Concentration of metabolites of valproic acid in plasma of epileptic patients.
    Löscher W
    Epilepsia; 1981 Apr; 22(2):169-78. PubMed ID: 6781893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy.
    Löscher W; Nau H; Siemes H
    Epilepsia; 1988; 29(3):311-6. PubMed ID: 3131137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary metabolites of valproic acid in epileptic patients.
    Katayama H; Watanabe M; Yoshitomi H; Yoshida H; Kimoto H; Kamiya A; Hayashi T; Akimura T
    Biol Pharm Bull; 1998 Mar; 21(3):304-7. PubMed ID: 9556166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticonvulsant activity of metabolites of valproic acid.
    Löscher W
    Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):158-63. PubMed ID: 6784685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of valproic acid and its metabolites during continued treatment in dogs.
    Löscher W
    J Vet Pharmacol Ther; 1981 Jun; 4(2):111-9. PubMed ID: 6818360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary excretion of valproate and some metabolites in chronically treated patients.
    Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
    Ther Drug Monit; 1989; 11(2):127-33. PubMed ID: 2497561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of metabolites of valproic acid in serum of humans, dog, rat, and mouse.
    Jakobs C; Löscher W
    Epilepsia; 1978 Dec; 19(6):591-602. PubMed ID: 104869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination.
    Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW
    Drug Metab Dispos; 2000 Jul; 28(7):857-64. PubMed ID: 10859160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
    Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.
    Kondo T; Otani K; Hirano T; Kaneko S; Fukushima Y
    Br J Clin Pharmacol; 1990 Jan; 29(1):116-9. PubMed ID: 2105099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid elimination rate and urinary excretion of its glucuronide conjugate in patients with epilepsy.
    Yoshida H; Hirozane K; Kimoto H; Hayashi T; Akiyama T; Katayama H; Watanabe M; Yoshitomi H; Kamiya A
    Biol Pharm Bull; 1999 Jul; 22(7):716-20. PubMed ID: 10443469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolite profiles in patients on high-dose valproate monotherapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsy Res; 1996 Oct; 25(2):107-12. PubMed ID: 8884168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation.
    Hooper WD; Franklin ME; Glue P; Banfield CR; Radwanski E; McLaughlin DB; McIntyre ME; Dickinson RG; Eadie MJ
    Epilepsia; 1996 Jan; 37(1):91-7. PubMed ID: 8603632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of LC-MS/MS vs chemiluminescent microparticle immunoassay in measuring the valproic acid concentration in plasma of epilepsy patients in a new perspective.
    Wang Z; Yun Y; Xie X; You C; Miao H; Zhang F; Gao S; Chen W
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28205314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ; Wang XD; Wang HS; Chen SD; Zhou LM; Li JL; Shu WY; Zhou JQ; Fang ZY; Zhang Y; Huang M
    Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.
    Fisher E; Siemes H; Pund R; Wittfoht W; Nau H
    Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative ion chemical ionization gas chromatography/mass spectrometry of valproic acid metabolites.
    Kassahun K; Burton R; Abbott FS
    Biomed Environ Mass Spectrom; 1989 Oct; 18(10):918-26. PubMed ID: 2508808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.